CTC Bio KRX:060590KOSDAQ
씨티씨바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h2
Articles, 7 days4
DART filings, 7 days0
Articles tracked7since Sep 11
In Q2 2026, CTC Bio reported revenue of ₩33.7bn, down 4.9% year on year, and operating profit of ₩3.8bn. CTC Bio (씨티씨바이오) appeared in 4 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 28 with 2 articles. The most common catalyst was contracts & orders (2).
Filing signals Profit +50% Screener
CTC Bio quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩33.7bn | -4.9% | ₩3.8bn margin 11.3% | ₩2.6bn |
| Q1 2026 | ₩34.4bn | +1.0% | ₩4.6bn margin 13.4% | ₩3.5bn |
| Q4 2025 derived | ₩31.6bn | -22.1% | ₩1.5bn margin 4.8% | ₩1.1bn |
| Q3 2025 | ₩31.8bn | -11.2% | ₩1.5bn margin 4.6% | ₩310m |
| Q2 2025 | ₩35.4bn | +1.7% | ₩2.3bn margin 6.4% | ₩1.2bn |
| Q1 2025 | ₩34.1bn | +2.7% | ₩916m margin 2.7% | ₩635m |
| Q4 2024 derived | ₩40.6bn | +15.5% | ₩812m margin 2.0% | ₩502m |
| Q3 2024 | ₩35.8bn | +14.8% | −₩3.0bn margin −8.5% | −₩3.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
CTC Bio top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4